key: cord-0316577-wejuabuo authors: Eales, O.; Walters, C. E.; Wang, H.; Haw, D.; Ainslie, K. E. C.; Atchinson, C.; Page, A.; Prosolek, S.; Trotter, A. J.; Le Viet, T.; Alikhan, N.-F.; Jackson, L. M.; Ludden, C.; The COVID-19 Genomics UK Consortium,; Ashby, D.; Donnelly, C. A.; Cooke, G.; Barclay, W.; Ward, H.; Darzi, A.; Elliott, P.; Riley, S. title: Characterising the persistence of RT-PCR positivity and incidence in a community survey of SARS-CoV-2 date: 2021-08-13 journal: nan DOI: 10.1101/2021.08.12.21261987 sha: 36183ea849127279df17cccc1836beb6790b93dc doc_id: 316577 cord_uid: wejuabuo Background Community surveys of SARS-CoV-2 RT-PCR swab-positivity provide prevalence estimates largely unaffected by biases from who presents for routine case testing. The REal-time Assessment of Community Transmission-1(REACT-1) has estimated swab-positivity approximately monthly since May 2020 in England from RT-PCR testing of self-administered throat and nose swabs in random non-overlapping cross-sectional community samples. Estimating infection incidence from swab-positivity requires an understanding of the persistence of RT-PCR swab positivity in the community. Methods During round 8 of REACT-1 from 6 January to 22 January 2021, of the 2,282 participants who tested RT-PCR positive, we recruited 896 (39%) from whom we collected up to two additional swabs for RT-PCR approximately 6 and 9 days after the initial swab. We estimated sensitivity and duration of positivity using an exponential model of positivity decay, for all participants and for subsets by initial N-gene cycle threshold (Ct) value, symptom status, lineage and age. Estimates of infection incidence were obtained for the entire duration of the REACT-1 study using P-splines. Results We estimated the overall sensitivity of REACT-1 to detect virus on a single swab as 0.79 (0.77, 0.81) and median duration of positivity following a positive test as 9.7 (8.9, 10.6) days. We found greater median duration of positivity where there was a low N-gene Ct value, in those exhibiting symptoms, or for infection with the Alpha variant. The estimated proportion of positive individuals detected on first swab, P0, was found to be higher for those with an initially low N-gene Ct value and those who were pre-symptomatic. When compared to swab-positivity, estimates of infection incidence over the duration of REACT-1 included sharper features with evident transient increases around the time of key changes in social distancing measures. Discussion Home self-swabbing for RT-PCR based on a single swab, as implemented in REACT-1, has high overall sensitivity. However, participants' time-since-infection, symptom status and viral lineage affect the probability of detection and the duration of positivity. These results validate previous efforts to estimate incidence of SARS-CoV-2 from swab-positivity data, and provide a reliable means to obtain community infection estimates to inform policy response. We estimated the overall sensitivity of REACT-1 to detect virus on a single swab as 0.79 (0.77, 0.81) and median duration of positivity following a positive test as 9.7 (8.9, 10.6) days. We found greater median duration of positivity where there was a low N-gene Ct value, in those exhibiting symptoms, or for infection with the Alpha variant. The estimated proportion of positive individuals detected on first swab, , was found to be higher for those with an 0 initially low N-gene Ct value and those who were pre-symptomatic. When compared to swab-positivity, estimates of infection incidence over the duration of REACT-1 included sharper features with evident transient increases around the time of key changes in social distancing measures. Home self-swabbing for RT-PCR based on a single swab, as implemented in REACT-1, has high overall sensitivity. However, participants' time-since-infection, symptom status and viral lineage affect the probability of detection and the duration of positivity. These results validate previous efforts to estimate incidence of SARS-CoV-2 from swab-positivity data, and provide a reliable means to obtain community infection estimates to inform policy response. Symptom-initiated community testing for SARS-CoV-2 is a vital public health intervention that enables the isolation of known positives and the quarantining of close contacts [1] . However, the trend of cases obtained from routine surveillance is often unreliable because of capacity issues and changing propensity to seek tests [2] . Therefore, data from representative community studies of swab positivity such as the REal-time Assessment of Community Transmission-1 (REACT-1) study [3] are used to infer prevalence of swab-positivity in order to maintain situational awareness during periods when routine testing is less reliable. In order to infer infection incidence from these data, estimates are required of test sensitivity and the duration that people continue to test positive, but these depend heavily on factors that will vary between settings and study designs. For example, estimates of sensitivity of RT-PCR to detect SARS-CoV-2 have been made using samples taken by health care professionals from hospitalized patients [4, 5] , and from small non-representative groups [6] . Also, the specific criteria used to declare results from RT-PCR assays as positive, such as use of multiple gene targets and limits of cycle threshold (Ct) values, vary from laboratory to laboratory. REACT-1 is tracking the spread of SARS-CoV-2 in England over time at national and regional scales and in different socio-demographic groups [3] , based on self-administered throat and nose swabs obtained from non-overlapping random samples of the population [7] . However, estimates of daily incidence during the pandemic have relied on unvalidated assumptions concerning RT-PCR sensitivity and the duration of RT-PCR positivity. Here, in a substudy of REACT-1 round 8 (6 January 2021 -22 January 2021) [8] we asked participants who tested positive to obtain two additional swabs approximately 5 days apart. In this way we aimed to estimate the study-specific sensitivity of RT-PCR based on a single swab, and the average duration for which individuals remained positive, allowing us to provide daily incidence estimates over time. Of the 2,282 individuals testing positive in round 8, 896 (39%) agreed to take part in this sub-study, of whom 874 (98%) had more than one successful RT-PCR test with valid date information (662 with three tests, 212 with two tests). The median interval between the first positive test and second test was 6 days, and it was 9 days between the first and third test, with the largest delay between the first and last test being 17 days. Of the 874 participants with at least one valid additional test: 323 (37%) were positive on all additional tests (237 with two additional tests and 86 with one additional test); 412 (47%) were negative on all 3 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.12.21261987 doi: medRxiv preprint additional tests (286 with two additional tests and 126 with one additional test); and the remainder had a mix of positive and negative results on additional tests ( Figure 1A ). We developed a statistical model of positivity to describe the probability of participants testing positive as a function of time since the first positive sample (see Methods). We fit an exponential decay in the probability of being positive, with a decay rate and initial proportion of positive individuals detected, , estimated from the data (Figure 2 ). For all participants, Table 1 ). With the estimates for (equivalent to the sensitivity of the study) and mean duration 0 positive (Table 1) we converted previous estimates of weighted swab-positivity for each round of REACT-1 into estimates of average daily incidence ( Fitting a P-spline model to incidence and swab-positivity separately (see Methods) we find that patterns in incidence preceded changes in swab-positivity ( Figure 3 ) and that features on the incidence time series were sharper than the corresponding features of the swab-positivity time series. For example, there was a more pronounced peak in mid-October in incidence compared with swab-positivity, which fell sharply until mid-November. From mid-November onwards incidence increased and appeared to begin decreasing in early January, though with no data from REACT-1 for December there was considerable uncertainty in the estimates for this period. From early May to beginning of July 2021, both incidence and swab-positivity increased exponentially. However, by the end of round 13 (12 July 2021) it appeared that incidence was no longer increasing, though with wide credible intervals on the P-spline. . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.12.21261987 doi: medRxiv preprint We found evidence of differences in the time course of positivity driven by a number of factors: Ct value, symptom status, lineage, and age ( Figure 2 , Table 1 , Supplementary Figure 1 ). Also, we extended the statistical model of positivity to include a plateau before the start of the exponential decay and fit models with and without the plateau to subsets of the data selecting the best-fitting version (see Methods). We found that the estimates of median duration of positivity and were dependent on 0 N-gene Ct value ( Figure 4 , Table 1 ). The estimate of was highest at 0.95 (0.91, 0.98) for 0 participants whose initial Ct value was in the lowest~1/3 (less than or equal to 24.5), indicating high sensitivity to detect strong positives, decreasing to 0.52 (0.39, 0.61) in those participants with a Ct value in the highest ~1/3 (greater than 32.5). The estimated median duration of positivity was highest in those with a Ct <= 24.5 at 14.8 (12.4, 18.9 ) days decreasing to 4.9 (4.0, 6.6) days for those with a Ct greater than 32.5. The best-fitting model for those with a Ct value less than 24.5, included a 4.0 (3.0, 4.5) day plateau before the exponential decay (difference in expected log predictive density [ELPD] = 9.5). In addition to positivity, we analysed Ct values across repeated tests for the same individuals proportion of individuals they decreased from the first test to subsequent tests. However, we were unable to estimate N-gene Ct values for 41% of second tests and 47% of third tests, either due to a negative test or because the Ct value was higher than the limit of reporting (N-gene Ct = 50). We found differences in the estimates of and the median duration of positivity according (Table 1) . Subsetting these individuals into those who reported any symptoms in subsequent tests (pre-symptomatics) and those who reported no symptoms (asymptomatics) also identified clear differences ( Figure 4 , Table 5 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 13, 2021. Table 1 ). We also fit models to random samples of individuals infected with Alpha variant, selected so that the proportion of individuals with initial N-gene Ct value <=24.5, 24.532.5 was the same as for those infected with wildtype; this led to a slight reduction in the estimated median duration of positivity for Alpha variant, but it was still greater than the corresponding value for those infected with wildtype (Supplementary Table 1 ). The best-fitting model for those infected with the Alpha variant, included a 3.4 (2.2, 4.2) day plateau before the exponential decay (difference in ELPD = 5.4). There were small differences in the estimates of and the median duration positive 0 between those aged 41-59 years and those aged 60 years and above, but no significant pairwise differences between those aged 18-40 years and these groups (Table 1 ). We estimate the overall sensitivity of the study based on a single swab to be ~79%, rising to 95% for strong positives, demonstrating why the RT-PCR remains the gold standard in testing for the presence of SARS-CoV-2. Additionally we characterised the median and mean duration that an individual remains positive after an initial positive test in REACT-1 at 10 and ~14 days respectively (assuming a continued exponential decay beyond the follow-up period of our study), comparable to and validating previous estimates [10] . With both sensitivity and duration of positivity well-characterised we were able to convert our previous estimates of swab-positivity into incidence allowing estimates of new daily 6 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 13, 2021. ; infections across the whole study period of REACT-1. This allowed us to assess the effects of various non-pharmaceutical interventions by comparing the patterns in incidence with the timing of changes in COVID-19 restrictions. For example, a fall in incidence was seen from mid-October 2020 suggesting that behaviour may have changed before the formal start of the lockdown introduced on 3 November 2020, and sooner than would be implied from the swab-positivity data. This is consistent with findings from a previous study that reported a decrease in mobility in the last two weeks of October 2020 [11] . The model used in calculating daily incidence has a number of limitations. Firstly we assumed an exponential decay to describe the probability of a participant testing positive in our study, which would not capture non-exponential longer-term trends in the waning of positivity. This limitation is unavoidable because our maximum follow-up was17 days after the initial positive infection, while it is known that people may remain positive for much longer periods [12] . Secondly, in estimating incidence we have assumed that the parameter estimates obtained for the decay of positivity from our round 8 substudy are representative of the entire study duration. Subgroup analysis showed there were differences in sensitivity and duration of positivity in individuals based on initial N-gene Ct value, symptomatology and viral lineage. With N-gene Ct value highly dependent on the contemporaneous growth rate of the pandemic [13] , the distribution of Ct values may vary between rounds. Furthermore, lineages responsible for infections changed over the study period with the emergence of the Alpha variant in late 2020 [14] , and the Delta variant in April 2021 [15] . We were unable to use lineage specific parameter estimates in estimates of infection incidence as lineage was only determined (via viral sequencing) in samples with lower Ct values (<34). The median and mean durations of positivity we report do not directly inform isolation and quarantine policy. For example, the shorter duration of positivity we estimate for asymptomatic positives does not immediately suggest a shorter duration of isolation for asymptomatic contacts, despite the persistence of RT-PCR-positivity likely indicating some level of continued infectiousness: from our results, we cannot estimate the time at which symptoms occur in the 1/3 of those who initially did not report symptoms. Also, isolation and quarantine policies often reflect upper limits for durations of positivity, such as the 90th, 95th or even 97.5th percentiles [16] , and must also take into account practical and logistical constraints on their implementation. In subgroup analyses, as noted, we obtained higher sensitivity estimates for those infections with a lower Ct value suggesting that the test is more sensitive for stronger positives predominantly indicating recent infections (Ct is lowest at around ~3 days [10] ). Furthermore, estimated sensitivity was highest in presymptomatic individuals, whereas it was comparable 7 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.12.21261987 doi: medRxiv preprint between asymptomatic and symptomatic individuals, again suggesting that RT-PCR testing is highly effective at detecting early stage infections. Similar to a previous analysis [10] we found that median duration of positivity was lower in asymptomatic individuals, compared to those exhibiting any symptoms or one or more of the most predictive COVID-19 symptoms. Previous estimates of the proportion of infections that are asymptomatic, based on RT-PCR testing, may therefore have been underestimated due to their shorter duration. Finally we indicate that Alpha variant infections may have a greater median duration of positivity than wildtype, similar to other work [6] , though with wide credible intervals. With the recent emergence of the Delta variant [15] in England, characterising any possible changes in RT-PCR test sensitivity and duration of positivity will be necessary to estimate infection incidence of Delta from swab-positivity data. Our study provides similar data on Ct values to previous studies [6, 10] that have estimated the duration of the proliferation and clearance stage of the virus. However, due to a lower rate of sampling in our study we are unable to estimate these parameters. The median duration of 6 days between the first and second test is greater than the estimated proliferation stage of ~3 days. Additionally as recruitment to our study was based upon an initial positive result, and we only had swab results up to a maximum of 17 days post-first swab, we were particularly misplaced in estimating the course of the virus, as we will not have captured individuals at both early and late stages of infection. As well as estimating test sensitivity and duration of positivity for the REACT-1 study, our results identify factors that will drive sensitivity and duration of positivity for community-based sampling more generally. Given likely reductions in many populations in the provision of routine community testing and in people's propensity to seek tests, representative community PCR-based surveys similar to REACT-1 can continue to provide valuable situational awareness during periods of rapid changes in infection incidence. The methods for REACT-1 have been described before [7] . Since May 2020 there have been 13 rounds of data collected, approximately every month (except December 2020). For each round of the study a random cross-section of the population of England ages 5 years and over is sent a letter inviting them to take part. The invitees are randomly selected at the lower tier local authority level (n=315) through the list of general practitioners patients held by the National Health Service (NHS) in England. Those participants that agree to take part are sent a self-administered swab test (parent/guardian administered for those aged 5 to 12 8 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.12.21261987 doi: medRxiv preprint years old). They also answer a short questionnaire providing information on age and other demographics as well as details on any symptoms that they exhibited in the month prior to their test. Swabs are collected in dry sample tubes and transported via cold chain to the laboratory for RT-PCR testing. In REACT-1, we obtain a single swab from each participant and test for N-gene and E-gene targets. We define a sample as positive if it has a valid positive signal for both gene targets (regardless of Ct value) or if it is positive only for N-gene with a Ct value equal to or lower than 37 [7] . During round 8 (6 January 2021 -22 January 2021) the study participants who tested positive were invited to take an additional two swab tests. For those who agreed, swabs were administered and collected as before. During round 8 of the study RT-PCR positive samples with a low enough N-gene Ct value (N-gene Ct value <34) and a high enough volume underwent genomic sequencing (Public Health England Research Ethics Governance Group (reference: R&D NR0195)). The methods have been described before [17] . In short, viral RNA was amplified using the ARTIC protocol [18] and sequence libraries were then prepared using CoronaHIT [19] . Raw sequence data were then analysed using the ARTIC bioinformatic pipeline [20] and lineage designation was performed using the machine learning-based assignment algorithm PangoLEARN [21] . Not all sequences obtained were of a sufficient quality for a lineage to be designated, and samples in which less than 50% of bases were covered were also deemed to have no lineage designation. Due to the repeat measurements in round 8 we were able to is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 13, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.12.21261987 doi: medRxiv preprint Estimates of the weighted swab-positivity for all 13 rounds of REACT-1 have previously been calculated [26] . Weighted swab-positivity is converted to average daily incidence by dividing by the sensitivity of the study ( from the decaying positivity model fit to all data), and by the 0 mean duration of positivity (estimated from the decaying positivity model). The daily infection incidence is converted to an estimate for the number of daily infections in England using mid-2020 population estimates [27] . Estimates of average daily infection incidence are calculated for the entire posterior distribution of and the mean duration of positivity with 0 weighted swab-positivity randomly sampled from a normal distribution, with mean value the central estimate and standard deviation the width of the 95% CI divided by 3.92. From this posterior the median and 95% confidence interval are estimated for average daily incidence. We fit a Bayesian P-spline model of incidence to the daily swab-positivity data for all 13 rounds of REACT-1. The period of time spanning from 50 days prior to the first day of the study to the last day of the study is segmented into regularly sized knots of approximately 5 days, with a further three knots defined before and after this period (to remove edge effects). A system of 4th order basis-splines (B-splines) is then defined over these knots, and the model of infection incidence is the linear combination of these B-splines. Overfitting of the model is minimised through the inclusion of a second-order random-walk prior distribution on the coefficients of the B-splines, , where is the coefficient for the = 2 −1 − −2 + ℎ B-spline, and is normally distributed with . The first two B-spline coefficients, ∼ (0, ρ 2 ) and , are assumed to have a uniform prior distribution. This prior distribution penalises 1 2 changes in the first derivative of the P-spline. The parameter controls the level of ρ penalisations and is assumed to have an uninformative inverse gamma prior distribution, . The P-spline of daily incidence is then converted into an estimate for ρ ∼ (0. 001, 0. 001) the daily swab-positivity through the equation where is the swab-positivity on the day, is the incidence (from the P-spline) on ℎ − the day, is the exponential decay rate and is the sensitivity of the test. The ( − ) ℎ exponential decay rate and sensitivity are taken to be the best estimates from the decaying positivity model. The summation should technically run from 0 to infinity but due to the need to compute it we take to be 50 which was selected to be large enough that the exponential 11 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 13, 2021. ; term in the model becomes negligible. By converting the daily incidence into a daily swab-positivity we are then able to fit our model to the daily data for swab-positivity that the study collects. The model is fit is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 13, 2021. Full list of COG-UK author's names and affiliations are available in this spreadsheet. . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.12.21261987 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.12.21261987 doi: medRxiv preprint Table 2 . Weighted swab-positivity, daily incidence rate and incidence for each round of REACT-1 with 95% confidence intervals. The number of individuals with each combination of test results. "1" represents a positive test result, "0" represents a negative test result, "X" that one test was undetermined and so excluded from the analysis. The ordering represents the order in which test results were obtained. (B) Distribution of changes in Ct value between the first (positive) test and following tests. Only tests with an accurate estimate of N-gene Ct value are included; those tests in which the N-gene Ct was not measured successfully which were included with an N-gene Ct value of 50 (the limit of detection) in panel A have not been included. (C) N-gene Ct value measured in repeat tests over time. Points show the data for the first measurement (red), second measurement (green) and third measurement (blue) of N-gene Ct value against time (jittered). The lines connect each individual's repeat measurements; decreases in Ct (dark grey) between first measurement and second measurement have been highlighted through a darker coloring. Points with a N-gene Ct value of 50 did not have any virus detected and so have been placed at the limiting value of the test. . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 13, 2021. ; Figure 2 : Best-fitting exponential decay model with no plateau (dark green line) and 95% confidence interval (green shaded region). Best-fitting exponential decay model with a plateau (dark orange) and 95% confidence interval (orange shaded region) are included for the subsets of data where the model was preferred. Data (black points) and 95% Binomial confidence intervals (black error bars) are included for the proportion of tests that were positive. (A) Model fit to all available data. (B,C) Model fits to subsets of the data based on the determined lineage (Alpha, wildtype). (D,E,F) Model fits to subsets of the data based on N-gene Ct value of the first test (Ct<=24.5, 24.532.5). (G,H,I) Model fits to subsets of the data based on symptom status: those reporting any symptoms in the month prior to the first test (Any symptoms), those reporting no symptoms prior to all their tests (Asymptomatic) and those reporting no symptoms prior to their first test but symptoms prior to subsequent tests (Pre-symptomatic). Note that the models are not fit to the data as presented, but to the exact ordering of test outcomes for each individual. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 13, 2021. ; Figure 3 . Comparison of inferred daily incidence and swab-positivity over 13 rounds of REACT-1 with a y-axis. Modelled estimate of daily incidence (red line, left hand y-axis) 10 with 95% credible interval (red shaded region) across all 13 rounds of REACT-1. Modelled estimate of daily swab positivity (black, right-hand y-axis) with 95% credible interval (grey shaded region) for all 13 rounds of REACT-1. Note that the model estimates are not shown for the period between rounds 7 and 8 (December) as there were no data to accurately capture the December peak in swab-positivity. Daily weighted observations (points) and 95% Binomial confidence intervals (vertical lines) are also shown for swab positivity (right hand axis). . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.12.21261987 doi: medRxiv preprint Figure 4 : Posterior probability density for the initial proportion testing positive, , and the 0 median duration of positivity. (A) Comparison of the posterior probability density for models fit to subsets of the data based on the N-gene Ct value of the first test (Ct<=24.5, 24.532.5). (B) Comparison of the posterior probability density for models fit to subsets of the data based on determined lineage (Alpha, wildtype). (C) Comparison of the posterior probability density for models fit to subsets of the data based on symptoms status in the month prior to their first test (Pre-symptomatic, any symptoms, most predictive COVID-19 symptoms, asymptomatic). Note that for the subset of data in which the lineage was determined to be the Alpha variant, and for the subset of data in which N-gene Ct value was less than 24.5 this is the density from the exponential decay model with an initial plateau (Model 2). . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.12.21261987 doi: medRxiv preprint Epidemic Surveillance of Covid-19: Considering Uncertainty and Under-Ascertainment Resurgence of SARS-CoV-2: Detection by community viral surveillance Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study Densely sampled viral trajectories suggest longer duration of acute infection with B.1.1.7 variant relative to non-B.1.1.7 SARS-CoV-2. bioRxiv. medRxiv REal-time Assessment of Community Transmission (REACT) of SARS-CoV-2 virus: Study protocol. Wellcome Open Research REACT-1 round 8 final report: high average prevalence with regional heterogeneity of trends in SARS-CoV-2 infection in the community in England during Get a free PCR test to check if you have coronavirus (COVID-19) Viral dynamics of acute SARS-CoV-2 infection. bioRxiv. medRxiv REACT-1 round 8 interim report: SARS-CoV-2 prevalence during the initial stages of the third national lockdown in England. bioRxiv. medRxiv At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data Estimating epidemiologic dynamics from cross-sectional viral load distributions. medRxiv Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England REACT-1 round 12 report: resurgence of SARS-CoV-2 infections in England associated with increased frequency of the Delta variant. bioRxiv. medRxiv On the quarantine period for ebola virus inferred from representative community samples. medRxiv nCoV-2019 sequencing protocol v3 (LoCost) CoronaHiT: high-throughput sequencing of SARS-CoV-2 genomes A Nextflow pipeline for running the ARTIC network's field bioinformatics tools. Github Phylogenetic Assignment of Named Global Outbreak LINeages (PANGOLIN) Practical Bayesian model evaluation using leave-one-out cross-validation and WAIC. arXiv REACT-1 round 13 final report: exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with Delta variant in England during May to July Population estimates for the These individual-level data are not yet available. The authors have declared no competing interest. The study was funded by the Department of Health and Social Care in England. Sequencing was provided through funding from COG-UK. Table 1 : Parameter estimates for the exponential decay model with no plateau (Model 1) and including a plateau (Model 2) for random subsets of individuals infected with the Alpha variant chosen to match the distribution of Ct values seen in individuals infected with wildtype.